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Abstract
Objectives: The aim of this study was to diagnosis oral lesions related to HIV infection in individuals followed in 
the General Hospital of the School of Medicine of Ribeirão Preto, University of São Paulo, Brazil. The presence 
of oral lesions was correlated with gender, age, smoking habit, levels of CD4 lymphocytes, HIV load, time of HIV 
seropositivity, AIDS condition, use of removable dental prosthesis, and use of HAART. Materials and Methods: 
340 HIV infected individuals were selected for this study, all participants of the study were examined by only one 
practiced dentist which performed anamnesis, peribuccal and oral examination. Results: Oral lesions were observed 
in 113 of 340 (33.2%) HIV infected individuals. These oral lesions included: oral candidiasis (17.7%) of pseudomem-
branous (10.8%) and of erythematous types (6.9%), angular cheilitis (13.9%), hairy leukoplakia (11.8%), and oral 
ulcers (2.1%). Oral candidiasis lesions were more frequently observed in women (p.033). Smoking addict participants 
presented a high frequency of tongue hairy leukoplakia (p.038) and a reduced frequency of oral ulcers (p.018). Hairy 
leukoplakia and pseudomembranous candidiasis were inversely correlated to CD4+L levels and directly correlated 
with HIV load, behaving as immune depression markers. Hairy leukoplakia and pseudomembranous candidiasis 
also showed an inverse correlation with HAART use (p<.0001). Patients using mobile dental prosthesis presented 
a high frequency of erythematous candidiasis (p.003). Conclusion: The inverse correlation with CD4+L level and 
the direct correlation with HIV load suggest that oral lesions could be used as alternative clinical markers for poor 
immune condition in HIV infected individuals.
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Introduction
HIV is a Lentivirus of the Retroviridae that has lympho-
cytes and monocytes as target cells (1, 2), and is transmit-
ted by contact with human contaminated fluids (3-5). 
HIV, the etiologic agent of  AIDS, has caused a huge 
outbreak with 38.6 million infections and 20 million 
deaths since the first description in 1981 thru 2003 (6). 
In Brazil, more than 360 000 AIDS cases were reported 
until 2004 (7).
Since 1996, the use of highly active antiretroviral therapy 
(HAART) has reduced fatalities and increased the quality 
of life of AIDS patients by decreasing the incidence of 
opportunistic infections (8). Brazil supplies free antiretro-
viral therapy to AIDS patients since 1996 and only in 2005, 
about 170,000 individuals received HAART (9).  
Oral lesions, most of  them related to opportunistic 
pathogens, represent an important problem to AIDS 
patients (10, 11). The aim of this study was to diagnosis 
oral lesions related to HIV infection in individuals from 
Ribeirão Preto, SP, Brazil. The presence of oral lesions 
was correlated with gender, age, smoking habit, levels of 
CD4 lymphocytes, HIV load, time of HIV seropositivity, 
AIDS condition, use of removable dental prosthesis, and 
use of HAART. 
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Materials and Methods
A number of 357 HIV infected individuals followed in the 
General Hospital of the School of Medicine of Ribeirão 
Preto, University of São Paulo (GH-SMRP-USP), and 
having more than 18 years old were selected for the study. 
Seventeen individuals that did not have CD4 lymphocyte 
counts performed in a period of  3 month before to 3 
month after oral examination were excluded of the study. 
Therefore, 340 HIV infected individuals were selected for 
this study which was carried out from january 2004 to 
march 2006.
All participants of the study were examined by only one 
practiced dentist which performed anamnesis, peribuccal 
and oral examination as well as palpation of lymphono-
des. The oral lesions were identified following the EC-
Clearinghouse on Oral Problems Related to HIV Infection 
and WHO Collaborating Centre on Oral Manifestations 
of the Immunodeficiency Virus, 1993 (12). Biopsies were 
performed only for diagnosis of five oral cancer suspected 
cases. 
The protocol of this study was previously approved by 
the Ethics Committee of the GH-SMRP-USP and the 
HIV infected patients only participated of the study after 
learning on the study objectives and signing a consent 
document.
The prevalence of the distinct oral lesions was correlated 
to gender, age, smoking habit, time of HIV seropositivity, 
presence of removable dental prosthesis, CD4+ lympho-
cyte (CD4+L) levels, HIV load, AIDS condition (13) and 
regular use of HAART by the participants. Smoking habit 
was only considered in individuals that used tobacco every 
day, at any amount.    
Only 288 participants were included in the analysis of 
oral lesions by fungus because 52 individuals were using 
antifungal drugs and therefore were excluded of the my-
cological analysis of the study.  
Looking for a correlation between oral lesions with CD4 
lymphocyte levels, it was used the t unpaired test. For 
the correlation of oral lesions with HIV load it was used 
the Mann-Whitney test. For other correlations of oral 
lesions, with gender, AIDS condition, use of removable 
dental prosthesis and use of HAART, chi squared and 
Fisher tests including Odds Ratio (OR) were used. For the 
correlation between oral lesions with age and time of HIV 
seropositivity, it was used the chi-squared test for trend. All 
statistical tests were considered significant when having a 
higher than 95% significance level (p<.05). GrafhPad 3.01 
and GrafhPad Prism 4.00 softwares (InStat, EUA) were 
used for this statistical analysis. 
Results
The 340 HIV infected individuals that participated of 
the study included 217 males (63.8%) and 123 females 
(36.1%), ranging from 18 to 77 years (median of 38 years). 
Two hundred seventy one participants (79.7%) referred a 
regular use of HAART. Smoking habit was referred by 152 
participants (44.7%). Three hundred participants (88.3%) 
had AIDS and, among them, opportunistic infections 
were referred by 285 (95 %). One hundred twenty three 
participants (36.2%) had removable dental prosthesis. 
These data are shown in Table 1. 
Oral lesions were observed in 113 participants (33.2% 
positivity) and included angular cheilitis (AC), hairy 
leukoplakia (HL), pseudomembranous candidiasis (PC), 
erythematous candidiasis (EC) and oral ulcers (OU), as 
shown in Table 2 
Women showed more oral candidiasis (26/109, 23.8%) 
than men (25/179, 14%) (p.033; OR: 1.93; confidencial 
interval (CI): 1.048 – 3.553). Oral lesions occurred in parti-
cipants at any age. OU was only observed in non-smoking 
participants (7/188, 3.72%, p.018). On the opposite, HL 
was more prevalent among smokers (24/152, 15.8%) than 
non-smokers (16/188, 8.5%, p .038; OR: 2.02; CI: 1.028 
– 3.950). 
Participants with oral lesions had 236 CD4+L/mm3 of 
blood as average and it was significantly lower than the 
352CD4+L/mm3 of blood average of those without oral 
lesions (p<.0001; CI: 59.364 – 172.84). HL and PC were 
observed among participants having as averages 189 
CD4+L/mm3 of blood and 171 CD4+L/mm3 of blood, 
respectively. For those that did not have HL or PC, CD4+L 
averages were 331 and 360 /mm3 of blood respectively 
(p.009; IC: 58.655 – 225.750 for HL and p<.0001; CI: 
94.894 – 283.75 for PC), as shown in Table 3.    
Medians of  HIV loads in blood were distinct among 
participants having or not having oral lesions, 12311 virus 
copies/ml and 75 virus copies/ml (p<.0001), respectively. 
HL and PC were associated to high HIV loads (p<.0001) 
and were more frequent among those having median HIV 
loads higher than 56000 virus copies/ml of blood. Parti-
cipants not having HP or PC showed median HIV loads 
under 110 virus copies/ml of blood, as shown in Table 3. 
PC was not observed in the 39 participants without AIDS 
(p.020).
AC was observed in participants having a shorter average 
time of HIV seropositivity (4.51 years) compared to those 
not having AC (6.16 years, p.023).
Oral lesions were more prevalent among participants using 
removable dental prosthesis (51/123, 41.4%) than in those 
not using this kind of prosthesis (62/217, 28.57%, p.015; 
OR: 1.77; CI: 1.113 – 2.817). EC was observed in 13.89% 
of the participants using removable dental prosthesis and 
in only 2.78% of those not using it (p.0003; OR: 5.64; CI: 
1.989 – 16.022). 
The prevalence of oral lesions among those participants 
using HAART (75/271, 27.67%) was significantly lower 
than this prevalence among those not using HAART 
(38/69, 55.07%, p< .0001; OR: 0.18; CI: 0.181 – 0.537). 
QA and EC were more prevalent among participants not 
using HAART compared to those using it but this diffe-
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 Oral lesions
Characteristics No. (%) Present Absent p value
Gender 0.6978
    Male 217 64 70 147
    Female 123 36 43 80
Age (years) 0.7735
    18 – 30 45 13 19 26
    20 – 30 149 44 48 101
    30 – 40 102 30 27 75
    >50 44 13 19 25
Smoking habit 0.0832
    Yes 152 45 58 94
    No 188 55 55 133
AIDS cases 0.1752
    Yes 300 88 104 196
    No 40 12 9 31
Time of AIDS diagnosis (years) 0.1577
    0 – 3 113 33 43 70
    4 – 7 114 33,5 37 77
    8 – 11 73 21,5 22 51
    >12 40 12 11 29
Use of dental prosthesis                       0.0212*
   Yes 123 36 51 72
   No 217 64 62 155
Use of HAART <0.0001*
    yes 271 80 75 196
    No 69 20 38 31
Type of oral lesion
Number of patients 
having the lesion
Frequency
(%)
Angular cheilits* 40 13.9%
Hairy leukoplakia 40 11.8%
Pseudomembranous candidiasis * 31 10.8%
Erythematous candidiasis * 20 6.9%
Oral ulcerations 7 2.1%
Herpes simplex 3 0.9%
Kaposi´s sarcoma 2 0.6%
Multifocal epitelial hyperplasia 1 0.3%
Pseudo-epitelial hyperplasia 1 0.3%
Melanic hiperpigmentation 1 0.3%
Lymphoma 1 0.3%
Median rombic glossitis 1 0.3%
Total of lesions/ total of participants** 148/340
Table 1.  Data of HIV infected individuals that participated of the study. 
* Statistically significant.
Table 2. Oral lesions observed in the HIV infected individuals that participated of the 
study. 
* Only 288 individuals participated of this analysis. **More than one type of oral lesion 
was found in some participants. 
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rence was not statistically significant (p.058 and p.060). 
HL and CP were less prevalent among participants using 
HAART compared to those not using it (p< .0001; OR 
0.25; CI: 0.1253 – 0.5001 for HL and p<.0001; OR 0.23; 
CI: 0.105 – 0.504 for CP). The frequency of each oral 
lesion also including the association with use of HAART, 
is shown in Table 4. 
   
Discussion
About 80% of the participants of the study were using 
HAART regularly. This high frequency of HAART use 
is probably stimulated by the offer of free antiretroviral 
medication by the Brazilian Ministry of Health. This is 
different of what happens in other third world countries 
such as Cambodia where patients have to purchase the 
anti-retroviral drugs and only 8.9% of them used HAART 
(14). However, despite of HAART use, systemic opportu-
nistic infections were observed in 84% of the participants 
of  the present study and it could be explained by the 
characteristics of  this HIV infected population, which 
had relevant health problems. That is the reason they were 
forwarded into the GH-SMRP-USP, a hospital that offers 
tertiary level assistance. Unfortunately, it was not possible 
to discriminate types and time of use of antiretroviral 
drugs by the participants of the present study.
Oral lesions were observed in 33.2% of the participants. 
 
Participants presenting oral 
lesion Participants not presenting oral lesion
Type of oral lesions*
Average of 
CD4+L/mm3
Median 
of virus 
copies/ml
no
Average of 
CD4+L/mm3)
Median of virus 
copies/ml
no
Angular cheilits 303 455 40 345 159 248
Hairy leukoplakia** 189 56831 40 331 108 300
Pseud. candidíases** 171 58025 31 360 69 257
Erythem candidíases 330 383 20 340    207,5 268
Oral ulcerations 300 50 7 314 350 333
Herpes simplex 85 3136330 3 314 350 337
Kaposi´s sarcoma 32 307593 2 316     326.50 338
Multifocal epithelial hyperplasia 124 50 1 315 350 339
Pseudo-epitelial hyperplasia 201 88908 1 314 350 339
Melanic hiperpigmentation 251 50 1 314 350 339
Lymphoma 353 20575 1 314 350 339
Median rombic glossite 211 116 1 316 350 339
With HAART
Without 
HAART
Type of oral lesions* Present Absent Present Absent p
Angular cheilits 28 205 12 43 0.0587
Hairy leukoplakia 22 249 18 51 <0.0001**
Pseudomembranous candidiasis 17 216 14 41 <0.0001**
Erythematous candidiasis 13 220 7 48 0.0607
Oral ulcerations 6 265 1 68 1.00
Herpes simplex 1 270 2 67 0.1060
Kaposi´s sarcoma 1 270 1 68 0.1060
Multifocal epithelial hyperplasia 1 37 0 43 0.4726
Pseudo-epitelial hiperplasia 1 270 0 69 1.00
Melanic hiperpigmentation 1 270 0 69 1.00
Lymphoma 0 271 1 68 0.2053
Median rombic glossite 1 270 0 69 1.00
Table 3. Frequency of oral lesion in HIV-infected participants according to average CD4+L and median HIV load in blood. 
*More than one type of oral lesion was found in some participants. ** Statistically significant (p<0,009). 
Table 4.  Frequency of oral lesions in HIV-infected participants including use of HAART.
* More than one type of oral lesion was found in some participants. ** Statistically significant. 
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The oral lesions more frequently observed were AC, HL, 
PC and EC. Other authors also reported a high frequency 
of oral candidiasis in HIV infected individuals. Ramirez-
Amador et al (15), in Mexico, found high frequencies of 
EC and PC. Anteyi et al (16), in Nigeria, detected more 
frequently PC and AC. 
Candidiasis lesions are usually caused by Candida albi-
cans, and are described as a precocious manifestation of 
AIDS (17, 18). In the present study, oral candidiasis was 
more prevalent in females (23.85%) than in males (13.97%, 
p.033) as previously reported by Campisi et al (19) in 
Italy, where 34.8% of women and 12.2% of men presented 
these lesions. The authors suggest that the occurrence of 
oral candididiasis could be gender-related. HL was more 
frequent among men (12.9%) than in women, but this 
difference was not statistically significant. Patton et al 
(20) observed that HL was significantly more frequent 
among men. The high prevalence of  HL, as reported 
by Ammatuna et al (21), should be related to a possible 
higher specificity of Epstein-Barr virus to oral epitelium 
of males. 
Oral lesions were observed in HIV infected participants at 
all ages without predominance, as previously reported in 
England by Eyeson et al (22). However, Sharma et al (23), 
in India, observed a higher risk of HL among individuals 
under 35 years old. 
AC was the most prevalent oral lesion (13.9%) in the pre-
sent study and it was associated to a short time of HIV 
seropositivity (p .023), as previously reported by Bendick 
et al (14), in Cambodia. Nevertheless, reasons for this 
association are unknown. 
The total oral lesions were more frequently observed 
among smoker participants (38.16%) than among non-
smokers (26.25%), but without statistical significance (p 
.08). However, HL was positively related to smoking habit 
(p.038). On the opposite OU was only observed in non-
smokers (p.018). Bendick et al (14), in Cambodia, also 
reported OU in non-smokers only. Muzyka and Glick 
(24) pointed that smokers have a large queratin layer at 
oral mucosa and it could protect to OU. Palacio et al, in 
1997 (25), reported that the smoking habit increased the 
frequency of oral lesions, especially oral candidiasis and 
oral warts. 
Oral lesions, especially EC, were more frequent among 
those participants using removable dental prosthesis 
(p.021 for oral lesions and p.0003 for EC). These lesions 
are probably caused by Candida sheltered in the irregular 
surface of the prosthesis (26), especially, in those that do 
not hygienize it properly (27).
The prevalence of oral lesions was inversely correlated 
with CD4+L levels of the participants, especially for HL 
and PC (p<.0001 for PC and p .009 for HL). Therefore, 
the occurrence of HL and PC could alert for immune de-
pression of HIV infected patients as previously observed 
by Miziara et al in 2006 (28), and Ramirez-Amador et 
al in 2001 (29). The last authors reported HL and PC as 
reliable clinical markers of immune depression.
In the present study, the presence of  oral lesions and 
specially HL and PC, were correlated to high HIV load 
(p<.0001). Adurogbangba et al (30) in Nigeria, Ramirez-
Amador et al (15) in Mexico, and Bravo et al (31) in Ve-
nezuela also reported the same association. In the present 
study, PC was only observed in AIDS patients (p .019). 
AIDS participants at C3 and B3 stage levels (13), had their 
oral lesions positively correlated with high HIV viremia 
and immune depression, both occurring in severe forms of 
the disease. Some authors reported oral lesions appearing 
early in the disease and behaving as precocious indicators 
of the immune depression of AIDS (32,33). Therefore, the 
incidence of oral lesions in HIV infected patients could be 
an useful tool to evaluate AIDS progression into a severe 
disease, especially in places were CD4+L count and HIV 
load exams are not available (34-36). 
A reduction on the prevalence of oral lesions has been 
reported in AIDS patients using HAART (22, 34, 36, 37). 
In the present study, the regular use of HAART, probably, 
reduced the prevalence of oral lesions and specially, redu-
ced HL and PC, which were significantly less frequent in 
these participants. The reduction of oral lesions is related 
to the immunity recovery obtained by the use of HAART 
(22, 34). Moura et al in 2006 (38) in Brazil, also reported 
that the regular use of HAART protected AIDS patients 
of  HL. A similar report was also made by Nicolatou-
Galitis et al in 2004 (39) in Greece, which reinforced the 
importance of HIV protease-inhibitor drugs on reducing 
oral lesions. 
In short, we show that oral lesions are common in Bra-
zilian HIV infected individuals and that these lesions 
are related to different individual characteristics. It is 
also shown that the regular use of HAART reduces the 
prevalence of oral lesions, and that oral lesions behave as 
immune depression markers which could be helpful for 
the management of AIDS patients. 
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